William J. Boyle

29.5k citations

66 papers · 19.7k indexed · 13 hit papers · h-index 31

Impact in

Orthopedics and Sports Medicine top 0.1%
- Bone health and osteoporosis research
- Bone and Joint Diseases
Oncology top 0.1%
- Bone health and treatments
- Cytokine Signaling Pathways and Interactions

Papers in

Oncology 31
- Bone health and treatments 13
- CAR-T cell therapy research 8
- HER2/EGFR in Cancer Research 5
Radiology, Nuclear Medicine and Imaging 18
- Monoclonal and Polyclonal Antibodies Research 17

Co-authors: David L. Lacey W. Scott Simonet Tony Hunter Josef Penninger Peter van der Geer Michael Karin Colin R. Dunstan Tod Smeal
Journals: Cancer Research (14 papers)Journal of the American Chemical Society (10 papers)Nature (4 papers)Cell (3 papers)Proceedings of the National Academy of Sciences (3 papers)
Partner nations: United States Canada South Korea

In The Last Decade

William J. Boyle

65 papers receiving 19.1k citations

Hit Papers

13 papers align trajectories log scale

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab 2012 · 495 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 Nature Reviews Drug Discovery
2003 Journal of Clinical Investigation
2003 Nature
2003 Journal of Clinical Investigation
2002 Annual Review of Immunology
2000 Journal of Bone and Mineral Research
2000 Cell
1999 Nature
1999 The Journal of Cell Biology
1991 Cell
1991 Methods in enzymology on CD-ROM/Methods in enzymology
1988 Nature
1988 Cell

Peers

Countries citing papers authored by William J. Boyle

Since Specialization

Citations

This map shows the geographic impact of William J. Boyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William J. Boyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William J. Boyle more than expected).

Fields of papers citing papers by William J. Boyle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William J. Boyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William J. Boyle. The network helps show where William J. Boyle may publish in the future.

Co-authors

The 25 scholars most cited alongside William J. Boyle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with William J. Boyle Line = papers co-authored together William J. Boyle links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract 743: Using a novel NextGen linker system to generate a conditionally active biologic (CAB) anti-nectin4-ADC demonstrates improved efficacy in pancreatic PDX cancer models and improved tolerability and toxicity profile in non-human primates Cancer Research ·Jing Wang, Jian Chen, Gerhard Frey, Siti Mistima Maat Salwah Che Mat, Charles Xing, Nick Weingaertner, Hwai W. Chang, William J. Boyle, Jay M. Short	2024	1
2	Abstract 2969: Targeting novel senescence markers by conditionally active biologics eliminates senescence-associated secretory phenotype in in vitro and in vivo models Cancer Research ·Jian Chen, Jian Wang, Н. А. Ямщиков, Cathy Chang, William J. Boyle, Jay M. Short	2024	0
3	Abstract 744: Novel conditionally active biologic (CAB) tetravalent T-cell engagers targeting solid tumors Cancer Research ·赖火祥, Siti Mistima Maat Salwah Che Mat, Patricia McNeeley, Charles Xing, Nick Weingaertner, Hwai W. Chang, Gerhard Frey, William J. Boyle, Jay M. Short	2024	1
4	Abstract 1871: Novel conditionally active bispecific HER2 x CD3 T cell engager targeting solid tumors Cancer Research ·赖火祥, Siti Mistima Maat Salwah Che Mat, Patricia McNeeley, Modesto Eusebio, Matthew C. Lucas, Charles Xing, Renchuan Jia, Mohd Thani Ahmad, Nick Weingaertner, Attachak Sattayanuruk, Cathy Chang, Gerhard Frey, William J. Boyle, Jay M. Short	2023	1
5	Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches Proceedings of the National Academy of Sciences ·Hwai Wen Chang, Gerhard Frey, Siti Mistima Maat Salwah Che Mat, Charles Xing, Lawrence Steinman, William J. Boyle, Jay M. Short	2021	37
6	Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab Nature Reviews Drug Discovery ·David L. Lacey, William J. Boyle, W. Scott Simonet, Paul J. Kostenuik, William C. Dougall, John K. Sullivan, Javier San Martín, Roger Dansey Hit paper breakdown →	2012	495
7	Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies Proceedings of the National Academy of Sciences ·Peter M. Bowers, Robert A. Horlick, Tamlyn Y. Neben, Т.А. Даниелян, Теофана Валентинова Димитрова, Restu Rikazillah Nurwan, Heather Jones, Monika Grabowska, Laurence J. Altobell, Xue Zhang, John L. Macomber, YiChieh Wu, J.道吉, Ashraf Bakry Abdelrazek, Betty Chau, Trevin Holland, VEBER COSTA, S Neben, William J. Boyle, David J. King	2011	78
8	Surrogate approaches in development of monoclonal antibodies Drug Discovery Today ·Gadi Gazit Bornstein, Scott L. Klakamp, Laura Andrews, William J. Boyle, Mohammad Tabrizi	2009	15
9	Role of RANK ligand in mediating increased bone resorption in early postmenopausal women Journal of Clinical Investigation ·Aylin Johanna Soriano Vanegas, Sundeep Khosla, Arunik Sanyal, William J. Boyle, David L. Lacey, B. Lawrence Riggs Hit paper breakdown →	2003	552
10	Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis Arthritis & Rheumatism ·Brad Bolon, Victoria Shalhoub, Paul J. Kostenuik, Giuseppe Campagnuolo, Sean Morony, William J. Boyle, Debra Zack, Ulrich Feige	2002	35
11	The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development Cell ·Jimmie E. Fata, Young‐Yun Kong, Lívia Beregi, Takehiko Sasaki, Junko Irie-Sasaki, Roger A. Moorehead, Robin Elliott, Sheila Scully, Evelyn B. Voura, David L. Lacey, William J. Boyle, Rama Khokha, Josef Penninger Hit paper breakdown →	2000	596
12	APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity Nature Immunology ·Gang Yu, T. Boone, John Delaney, Nessa Hawkins, Michael J. Kelley, M. Ramakrishnan, Susan McCabe, Stefania Siccardi, Masayo Kornuc, Xing-Zhong Xia, Jane Guo, Marina Stolina, William J. Boyle, Ildiko Sarosi, Hailing Hsu, Giorgio Senaldi, Lars E. Theill	2000	306
13	Osteoprotegerin Ligand Modulates Murine Osteoclast Survival in Vitro and in Vivo American Journal Of Pathology ·David L. Lacey, Hong Tan, John Lu, Steven L. Kaufman, Gwyneth Van, Jennifer Masters, Alana Rattan, Sheila Scully, Frederick A. Fletcher, Todd Juan, Michael J. Kelley, Teresa L. Burgess, William J. Boyle, Anthony Polverino	2000	321
14	Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis The Journal of Experimental Medicine ·Hosung Min, Sean Morony, Ildiko Sarosi, Colin R. Dunstan, Casey Capparelli, Sheila Scully, Gwyneth Van, Steve Kaufman, Paul J. Kostenuik, David L. Lacey, William J. Boyle, W. Scott Simonet	2000	439
15	OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature ·Young‐Yun Kong, Hiroki Yoshida, Ildiko Sarosi, Hong‐Lin Tan, Emma Timms, Casey Capparelli, Sean Morony, Antonio Oliveira-dos-Santos, Gwyneth Van, Annick Itié, Wilson Khoo, Andrew Wakeham, Colin R. Dunstan, David L. Lacey, Tak W. Mak, William J. Boyle, Josef Penninger Hit paper breakdown →	1999	2748
16	ATAR, a Novel Tumor Necrosis Factor Receptor Family Member, Signals through TRAF2 and TRAF5 Journal of Biological Chemistry ·Hailing Hsu, 赵万鹏, Anne Colombero, Robin Elliott, Michael J. Kelley, William J. Boyle	1997	148
17	B61 is a ligand for the ECK receptor protein-tyrosine kinase Nature ·Tòmas Puig, R.W.G. Hunt, 琛赵, William J. Boyle, Vann P. Parker, Richard Lindberg, Hsieng S. Lu, Anne Colombero, Robin Elliott, Brenda Guthrie, Carley E Johnson, Omotosho Mohammed Soladoye, Robert Toso, Ming Zhang, Ilham Hatta, С.П. Ломов, Brian Varnum, Yosef Yarden, Tony Hunter, Gary M. Fox	1994	194
18	Growth factors and tyrosine kinase receptors during development and cancer Current Opinion in Oncology ·William J. Boyle	1992	12
19	Oncogene jun encodes a sequence-specific trans- activator similar to AP-1 Nature ·Peter Angel, Elizabeth A. Allegretto, S.T. Okino, Kazue Hattori, William J. Boyle, Tony Hunter, Michael Karin Hit paper breakdown →	1988	867
20	Equilibrium and kinetic acidities of nitroalkanes and their relation to transition state structures Journal of the American Chemical Society ·F. G. Bordwell, William J. Boyle, Pratibha Sahu	1970	41

About William J. Boyle

William J. Boyle is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Immunology, Cancer Research and Biotechnology, having authored 66 papers that have together received 19.7k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (17 papers), Bone Metabolism and Diseases (16 papers), Bone health and treatments (13 papers), CAR-T cell therapy research (8 papers), NF-κB Signaling Pathways (8 papers), Chemical Reaction Mechanisms (6 papers), Immunotherapy and Immune Responses (5 papers) and HER2/EGFR in Cancer Research (5 papers). The work is most often cited by research in Orthopedics and Sports Medicine (3.3k citations), Oncology (8.5k citations), Molecular Biology (14.0k citations), Cancer Research (3.0k citations) and Immunology (3.0k citations). William J. Boyle has collaborated with scholars based in United States, Canada and South Korea. Frequent co-authors include David L. Lacey, W. Scott Simonet, Tony Hunter, Josef Penninger, Peter van der Geer, Michael Karin, Colin R. Dunstan, Tod Smeal, B. Lawrence Riggs and Sundeep Khosla. Their work appears in journals such as Cancer Research, Journal of the American Chemical Society, Nature, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact